TAK
NYSETakeda Pharmaceutical Company Limited
Price$17.16+0.04 (+0.23%)
01:30 PM07:45 PM
News · 26 weeks112+171%
2026-01-182026-07-12
Mix6990d
- Insider37(54%)
- SEC Filings19(28%)
- Other11(16%)
- Earnings1(1%)
- Leadership1(1%)
Latest news
25 items- PRTakeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis StudiesOn average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda ((TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent ora
- PRTakeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal ProductsMinistry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased Initiative Takeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation Network Collaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients Takeda (NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today a
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- INSIDERDirector Gillis Steven was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) to satisfy withholding obligation4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Maraganore John was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (for withholding tax)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Reed Kimberly A. was granted 3,800 units of Ordinary Shares, increasing direct ownership by 58% to 10,400 units (SEC Form 4) (tax withholding)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Iijima Masami was granted 1,800 units of Ordinary Shares, increasing direct ownership by 14% to 14,601 units (SEC Form 4) to satisfy withholding tax4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Broussard Bruce D was granted 3,800 units of American Depositary Shares, increasing direct ownership by 478% to 4,595 units (SEC Form 4) (withholding obligation)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Stoffels Paulus was granted 3,800 units of Ordinary Shares (SEC Form 4) to cover withholding tax4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Kimura Koichiro was granted 1,800 units of Ordinary Shares (SEC Form 4) (tax liability)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERDirector Tsusaka Miki was granted 1,800 units of Ordinary Shares, increasing direct ownership by 28% to 8,200 units (SEC Form 4) (withholding obligation)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, Japan Pharma B.U. Miyabashira Asuka was granted 1,500 units of Ordinary Shares, increasing direct ownership by 50% to 4,500 units (SEC Form 4) (tax liability)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Financial Officer Furuta Milano was granted 12,300 units of Ordinary Shares, increasing direct ownership by 21% to 70,200 units (SEC Form 4) (tax withholding)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, IBU Platford Giles Richard was granted 49,558 units of American Depositary Shares, increasing direct ownership by 17% to 346,921 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Comm. & Gov. Officer Smoter Jennifer Marie was granted 18,808 units of American Depositary Shares (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, PDT BU Ibrahim Ramy Riad Ahmed was granted 25,078 units of American Depositary Shares, increasing direct ownership by 30% to 109,865 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Human Resources Officer Greenway Nicola Deidre Petal was granted 22,570 units of American Depositary Shares, increasing direct ownership by 31% to 94,406 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Medical Officer Farajallah Awny Samaan Botros was granted 17,554 units of American Depositary Shares, increasing direct ownership by 16% to 130,183 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERGlobal General Counsel Furney Natalie Anne Marie was granted 43,886 units of American Depositary Shares, increasing direct ownership by 23% to 235,166 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, U.S. Business Unit Pacheco Rhonda Janice was granted 50,156 units of American Depositary Shares, increasing direct ownership by 34% to 199,408 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERHead, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,586 units of American Depositary Shares, increasing direct ownership by 16% to 199,934 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Data & Tech. Officer Ricci Gabriele was granted 37,616 units of American Depositary Shares, increasing direct ownership by 24% to 196,742 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPres., Global Supply & Quality Shannon Elaine Mary was granted 30,094 units of American Depositary Shares, increasing direct ownership by 52% to 87,674 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Transformation Officer Duprey Lauren Rusckowski was granted 45,140 units of American Depositary Shares, increasing direct ownership by 20% to 273,643 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
TAK FAQ
8 questionsWhat does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD...Where does TAK stock trade?
Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE.What sector and industry is TAK in?
Takeda Pharmaceutical Company Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Takeda Pharmaceutical Company Limited go public?
Takeda Pharmaceutical Company Limited (TAK) completed its IPO in 2018.Does TAK pay a dividend?
TAK's most recent ex-dividend date was 2026-03-31 with a cash dividend of $0.25 per share. No future ex-date is on file yet.What are analysts saying about TAK?
Takeda Pharmaceutical Company Limited has had 6 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-04-08. Recent price targets range from $2000.00 to $2400.00.What companies are similar to TAK?
Notable peers in the same industry include ABBV (AbbVie Inc.), AZN (AstraZeneca PLC), AMGN (Amgen Inc.), BMY (Bristol-Myers Squibb Company), SNY (Sanofi). Compare TAK side-by-side with any of them on Quantisnow.How can I track TAK on Quantisnow?
Quantisnow aggregates Takeda Pharmaceutical Company Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TAK to receive live email and push alerts on every new disclosure.